Benzinga | Nov 8, 2021 10:13AM EST

Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial

* Bristol Myers Squibb & Co (NYSE:BMY) has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC).

* The trial evaluated Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as neoadjuvant treatment.

* The study met the primary endpoint of improved event-free survival (EFS). Opdivo/Chemo combo showed a statistically significant and clinically meaningful improvement in EFS compared to chemotherapy alone.

* This combination previously showed a significant improvement of pathologic complete response (pCR), the trial's other primary endpoint.

* The Company will complete a full evaluation of the available CheckMate -816 data and share the results at an upcoming medical conference.

* Price Action: BMY shares are up 0.60% at $59.80 during the market session on the last check Monday.